Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
Provided By GlobeNewswire
Last update: Nov 5, 2024
-- Third quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $33.3 million --
-- Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access program --
Read more at globenewswire.com
